US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

25.58 -0.04 (-0.16%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,214,237
Open 26.80
Bid (Size) 25.00 (1,000)
Ask (Size) 26.00 (1,100)
Prev. Close 25.62
Today's Range 25.51 - 26.92
52wk Range 15.96 - 34.06
Shares Outstanding 956,637,360
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
From Zai Lab Limited
Via Business Wire

Performance

52-Week Range 24.9% below 52-week high
25.58
15.9652W Low 34.0652W High
1 Week 5.0% below 1-week high
23.711W Low 26.921W High

Zai Lab Limited - American Depositary Shares (ZLAB) traded between $15.96 and $34.06 over the past 52 weeks and last traded at $25.58, 24.9% below its 52-week high. Over the past week it ranged between $23.71 and $26.92.

Past 12 Months
-2.9%
+0.7%
+32.2%
+21.8%
+47.6%
-23.2%
1W -$0.76
1M +$0.17
3M +$6.23
6M +$4.58
YTD +$8.25
1Y -$7.73

ZLAB was -23.2% over the past year, +21.8% over six months, +47.6% year to date, -2.9% in the last week.

12 Months vs Market
ZLAB
-23.2%
DIA
+10.2%
SPY
+16.0%
QQQ
+25.0%
IWM
+14.0%

Over the past 12 months ZLAB returned -23.2% versus DIA (Dow) +10.2%, SPY (S&P 500) +16.0%, QQQ (Nasdaq 100) +25.0% and IWM (Russell 2000) +14.0%.

Volume & Liquidity 1.27× 3-mo avg
Today 1,214,237 3-mo avg 957.5K
1W
865.9K
1M
852.9K
3M
957.5K
6M
923.0K
YTD
863.1K
1Y
860.2K

ZLAB most recently traded 1,214,237 shares against a 3-month average daily volume of 957.5K.

More News

Read More
News headline image
Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Zai Lab Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
News headline image
U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab (ZLAB) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Zai Lab Announces Changes to Senior Leadership Team
From Zai Lab Limited
Via Business Wire
News headline image
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗
Via The Motley Fool
Topics Economy Regulatory Compliance
News headline image
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
From Zai Lab Limited
Via Business Wire

Frequently Asked Questions

Is Zai Lab Limited - American Depositary Shares publicly traded?
Yes, Zai Lab Limited - American Depositary Shares is publicly traded.
What exchange does Zai Lab Limited - American Depositary Shares trade on?
Zai Lab Limited - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Zai Lab Limited - American Depositary Shares?
The ticker symbol for Zai Lab Limited - American Depositary Shares is ZLAB on the Nasdaq Stock Market
What is the current price of Zai Lab Limited - American Depositary Shares?
The current price of Zai Lab Limited - American Depositary Shares is 25.58
When was Zai Lab Limited - American Depositary Shares last traded?
The last trade of Zai Lab Limited - American Depositary Shares was at 10/06/26 04:00 PM ET
What is the market capitalization of Zai Lab Limited - American Depositary Shares?
The market capitalization of Zai Lab Limited - American Depositary Shares is 24.47B
How many shares of Zai Lab Limited - American Depositary Shares are outstanding?
Zai Lab Limited - American Depositary Shares has 24B shares outstanding.